We also manufactured CAR-T cells with patient-derived T-cells within the scope of the clinical trial “Study of CD19 Specific CAR Positive T-cells (CAR-T) in ALL and NHL (ISIKOK-19)” (ClinicalTrials.gov Identifier: NCT04206943). Here, CD19 is linked to acute lymphoblastic leukemia.